SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* 2022 Third Quarterly Report" published by Shanghai Junshi Biosciences Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for reference purpose only. The unaudited financial data set out in this announcement is prepared in accordance with the accounting principles of the People's Republic of China instead of the International Financial Reporting Standards, and is prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only. The following is a translation of the 2022 Third Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By Order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, PRC, 30 October 2022

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive directors.

* *For identification purpose only*

Stock code：688180 Abbreviation: Junshi Bio

Shanghai Junshi Biosciences Co., Ltd.*
2022 Third Quarterly Report

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

IMPORTANT NOTICE

The board, the board of supervisors and the directors, supervisors and senior management of the Company undertake that the information in this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omissions, and assume several and joint liabilities in respect of the information in this report.

The person in charge of the Company, the person in charge of accounting affairs, and the person in charge of the accounting office (head of accounting department), hereby guarantee that the financial statements contained in this quarterly report are true, accurate and complete.

Whether the financial statements contained in this third quarterly report have been audited

☐Yes √No

I. Key financial data

(I) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Items	During the reporting period	Changes year-on-year (%)	From the beginning of the year to the end of the reporting period	Changes year-on-year (%)

Operating income	272,333,274.63	-54.91	1,218,381,861.73	-55.18
Net loss attributable to shareholders of the Company	-682,324,554.11	Not applicable	-1,594,729,564.22	Not applicable
Net loss attributable to the shareholders of the Company after deducting non-recurring profit and loss	-700,604,045.18	Not applicable	-1,646,968,461.29	Not applicable
Net cash flow from operating activities	Not applicable	Not applicable	-1,117,489,221.19	Not applicable
Basic earnings per share (yuan/share)	-0.75	Not applicable	-1.75	Not applicable
Diluted earnings per share (yuan/share)	-0.75	Not applicable	-1.75	Not applicable
Weighted average return on net assets (%)	-9.97	Decreased by 4.87 percentage points	-21.72	Decreased by 15.60 percentage points
Total research and development investment	573,876,203.31	20.74	1,636,118,643.63	15.01
Research and development investment as a percentage of operating income (%)	210.73	Increased by 132.03 percentage points	134.29	Increased by 81.96 percentage points
	As at the end of the reporting period	As at the end of the previous year		Increase/decrease at the end of the reporting period compared with the end of the previous year (%)
Total assets	9,581,031,208.80	11,034,911,100.95		-13.18
Owner's equity attributable to the shareholders of the Company	6,555,742,303.66	7,945,095,398.41		-17.49

Note 1: "the reporting period" refers to the period of three months commencing from the beginning of this quarter to the end of this quarter, same for below;

Note 2: Operating income during the reporting period mainly represents the sales revenue of Toripalimab Injection (trade name: 拓益® (TUOYI®), product code: JS001) from its commercialization in the domestic market. The sales revenue of TUOYI® in the third quarter of 2022 was approximately RMB 218 million, with three consecutive quarters of sequential growth. Thus, the sales of TUOYI® in the domestic market has gradually entered a virtuous cycle. As at the end of the reporting period, six indications of TUOYI® have been approved in China, and it is expected that with the approval of more indications and the advantages of the prospective layout of postoperative adjuvant/perioperative therapy, there is still much space for sales revenue growth of TUOYI® in the domestic market.

(II) Non-recurring gains and losses items and amounts

Unit: Yuan Currency: RMB

Items	Amount for the reporting period	From the beginning of the year to the end of the reporting period
Gains or losses from the disposal of non-current assets	-100,186.31	60,874,211.39
Government grants that are recognized in profit or loss for the period (other than government grants which are closely related to the Company's normal business operations, which comply with national policies and continuously enjoyed at fixed amount or quantity in accordance with certain standards)	11,544,855.03	19,765,259.31
Profit or loss from changes in fair value from holding of financial assets held for trading, derivative financial assets, financial liabilities held for trading and derivative financial liabilities, and investment income from disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments except for effective hedging transactions related to the Company's normal business operations	6,201,893.88	-16,472,481.41
Other non-operating income and expenses apart from the aforesaid items	418,364.86	-10,672,966.94
Less: Effect of income tax	64,693.59	1,583,832.94
Effect of minority interests (after tax)	-279,257.20	-328,707.66
Total	18,279,491.07	52,238,897.07

Description on defining the non-recurring gains or losses items set out in the "Explanatory Announcement No. 1 Regarding Information Disclosure for Companies Publicly Issuing Securities –Non-recurring Gains or Losses"* (《公開發行證券的公司信息披露解釋性公告第 1 號——非經常性損益》) as recurring gains or losses items

☐Applicable √Not applicable

(III) Descriptions and reasons for changes in major accounting data and financial indicators

√Applicable ☐Not applicable

Items	Changes（%）	Major reasons
Operating income_ During the reporting period	-54.91	Mainly due to the inability of the increase in the sales revenue of drugs to offset the impact of the decrease in licensing income compared with the same period of the previous year.
Operating income_From the beginning of the year to the end of the reporting period	-55.18	
Net loss attributable to shareholders of the Company_ During the reporting period	Not applicable	Mainly due to the decline in operating income compared with the same period of the previous year, which led to an increase of loss.
Net loss attributable to shareholders of the Company_From the beginning of the year to the end of the reporting period	Not applicable	
Net loss attributable to the shareholders of the Company after deducting non-recurring profit and loss_ During the reporting period	Not applicable	
Net loss attributable to the shareholders of the Company after deducting non-recurring profit and loss_From the beginning of the year to the end of the reporting period	Not applicable	
Net cash flow from operating activities_From the beginning of the year to the end of the reporting period	Not applicable	Mainly due to a decrease in licensing income compared to the same period of the previous year.
Basic earnings per share (yuan/share) _ During the reporting period	Not applicable	Mainly due to the decline in operating income compared with the same period of the previous year, which led to an increase of loss.
Basic earnings per share (yuan/share) _From the beginning of the year to the end of the reporting period	Not applicable	
Diluted earnings per share (yuan/share) _ During the reporting period	Not applicable	
Diluted earnings per share (yuan/share) _From the beginning of the year to the end of the reporting period	Not applicable	

Research and development investment as a percentage of operating income (%)_During the reporting period	Increased by 132.03 percentage points	Mainly due to the decline in operating income compared with the same period of the previous year.
Research and development investment as a percentage of operating income (%)_From the beginning of the year to the end of the reporting period	Increased by 81.96 percentage points	

II. Shareholder Information

(I) Particulars of total number of ordinary shareholders and preference shareholders with voting rights restored and shareholding of top ten shareholders

Unit: Share

<table>
<tr><td>Total number of holders of ordinary shares as at the end of the reporting period</td><td colspan="3">35,996</td><td colspan="2">Total number of preference shareholders with voting rights restored as at the end of the reporting period (if any)</td><td colspan="2">Not applicable</td></tr>
<tr><td colspan="8">Particulars of shareholding of the top 10 shareholders</td></tr>
<tr><td rowspan="2">Name of shareholder</td><td rowspan="2">Nature of shareholder</td><td rowspan="2">Number of shares held</td><td rowspan="2">Shareholding percentage (%)</td><td rowspan="2">Number of shares held subject to trading restrictions</td><td rowspan="2">Number of restricted shares including shares lent for securities refinancing</td><td colspan="2">Pledged, marked or frozen shares</td></tr>
<tr><td>Status of shares</td><td>Number of shares</td></tr>
<tr><td>HKSCC NOMINEES LIMITED</td><td>Unknown</td><td>219,291,230</td><td>24.03</td><td>0</td><td>0</td><td>Unknown</td><td>-</td></tr>
<tr><td>Xiong Jun</td><td>Domestic natural person</td><td>87,754,018</td><td>9.62</td><td>87,252,968</td><td>87,252,968</td><td>Nil</td><td>0</td></tr>
<tr><td>Shanghai Tanying Investment Partnership (LP)* (上海檀英投資合夥企業(有限合夥))</td><td>Other</td><td>76,590,000</td><td>8.39</td><td>0</td><td>0</td><td>Nil</td><td>0</td></tr>
</table>

Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫 藥管理合夥企業（有 限合夥))	Other	43,584,000	4.78	43,584,000	43,584,000	Nil	0
Xiong Fengxiang	Domestic natural person	41,060,000	4.50	41,060,000	41,060,000	Nil	0
Zhou Yuqing	Domestic natural person	21,680,800	2.38	21,680,800	21,680,800	Nil	0
Feng Hui	Domestic natural person	13,140,000	1.44	13,140,000	13,140,000	Nil	0
Hong Kong Securities Clearing Company Limited	Foreign legal person	12,531,369	1.37	0	0	Nil	0
China Merchants Bank Co., Ltd. - Huaxia SSE STAR Market 50 Constituent Trading Open-end Index Securities Investment Fund* (招商銀行股份有限公司－華夏上證科創板 50 成份交易型開放式指數證券投資基金)	Other	11,646,642	1.28	0	0	Nil	0
Zhang Jun	Domestic natural person	8,989,625	0.99	0	0	Nil	0

Particulars of shareholdings of the top 10 shareholders not subject to trading restrictions			
Name of Shareholder	Number of tradable shares held not subject to trading restrictions	Type and number of shares	
		Type of shares	Number of shares
HKSCC NOMINEES LIMITED	219,291,230	Overseas listed foreign shares	219,291,230

Shanghai Tanying Investment Partnership (LP)* (上海檀英投資合 夥企業(有限合夥))	76,590,000	RMB ordinary shares	76,590,000
Hong Kong Securities Clearing Company Limited	12,531,369	RMB ordinary shares	12,531,369
China Merchants Bank Co., Ltd. - Huaxia SSE STAR Market 50 Constituent Trading Open-end Index Securities Investment Fund* (招商銀行股份有限公司－華夏上證科創板 50 成份交易型開放式指數證券投資基金)	11,646,642	RMB ordinary shares	11,646,642
Zhang Jun	8,989,625	RMB ordinary shares	8,989,625
Huang Fei	7,747,925	RMB ordinary shares	7,747,925
Shi Wen	7,465,012	RMB ordinary shares	7,465,012
Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund (中國銀行股份有限公司－招商國證生物醫藥指數分級證券投資基金)	6,151,307	RMB ordinary shares	6,151,307
Du Yali	5,882,000	RMB ordinary shares	5,882,000

Industrial and Commercial Bank of China Limited – E Fund SSE STAR 50 Exchange Traded Funds* (中國工商銀行—易方達上證科創板 50 成份交易型開放式指數證券投資基金)	4,754,101	RMB ordinary shares	4,754,101
Description of the related party relationship or acting-in-concert arrangement among the above shareholders	Among the above shareholders, Xiong Fengxiang and Xiong Jun have a father-son relationship and are the controlling shareholders and actual controllers of the Company. Xiong Jun and Xiong Fengxiang are acting in concert with Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫藥管理合夥企業（有限合夥)) ("Ruiyuan Shengben") and Zhou Yuqing. Xiong Jun holds 40% of the equity interest in Shenzhen Qianhai Yuanben Equity Investment Fund Management Co., Ltd.* (深圳前海源本股權投資基金管理有限公司), being Ruiyuan Shengben's managing partner. Ruiyuan Shengben is held as to 5.1% and 1.39% by Zhou Yuqing and Huang Fei, respectively. Zhang Jun and Huang Fei have a spousal relationship. Save for the above description, the Company is not aware whether the other shareholders have related party relationship or whether the other shareholders are acting-in-concert parties under relevant regulations.		
Description on the top 10 shareholders and the top 10 shareholders not subject to trading restrictions engaging in margin trading and securities financing, if any	Among the above shareholders, Zhang Jun holds 4,989,625 shares of the Company through ordinary securities account and 4,000,000 shares through margin account, amounting to a total of 8,989,625 shares of the Company. Huang Fei holds 2,497,925 shares of the Company through ordinary securities account and 5,250,000 shares through margin account, amounting to a total of 7,747,925 shares of the Company. Shi Wen holds 0 shares of the Company through ordinary securities account 7,465,012 shares through margin account, amounting to a total of 7,465,012 shares of the Company.		

Note: 1. As at the end of the reporting period, among all the ordinary shareholders, there are 35,988 holders of A shares and 8 holders of H shares, amounting to a total of 35,996 shareholders;

Note 2. HKSCC NOMINEES LIMITED holds shares on behalf of various clients.

III. Other Significant Information

Other significant information about the operational results of the Company during the reporting period that requires investors' attention

□Applicable √Not applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Types of audit opinion

□Applicable √Not applicable

(II) Financial statement

CONSOLIDATED BALANCE SHEET

30 September 2022

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Items	30 September 2022	31 December 2021
Current assets:		
Cash and bank balances	3,064,825,595.33	3,506,637,890.39
Notes receivable		7,690,139.10
Accounts receivable	289,586,600.85	1,293,122,136.21
Prepayments	279,884,853.86	389,753,382.63
Other receivables	19,567,788.83	28,053,132.85
Including: Interests receivable		
Dividends receivable		
Inventories	537,280,841.89	484,601,367.48
Non-current assets due within one year	2,382,671.02	1,532,929.35
Other current assets	68,254,274.37	133,500,475.11
Total current assets	4,261,782,626.15	5,844,891,453.12
Non-current assets:		
Long-term equity investments	529,995,159.69	457,791,434.27
Other equity instruments investments	170,026,043.63	253,575,159.55
Other non-current financial assets	765,299,559.58	773,532,521.25
Fixed assets	1,783,034,545.90	1,882,275,784.87
Construction in progress	1,086,275,793.43	801,933,713.18
Right-of-use-assets	163,932,783.81	117,253,858.99
Intangible assets	318,597,134.03	264,979,896.47
Long-term prepaid expenses	23,747,097.25	27,792,436.42
Deferred tax assets	127,639,075.40	88,549,730.70
Other non-current assets	350,701,389.93	522,335,112.13
Total non-current assets	5,319,248,582.65	5,190,019,647.83
Total assets	9,581,031,208.80	11,034,911,100.95
Current liabilities:		
Short-term borrowings	448,244,979.36	

Notes payable		466,042.42
Accounts payable	900,479,258.17	1,584,702,519.58
Contract liabilities	9,680,195.58	45,796,586.82
Payroll payable	139,360,637.23	213,776,616.22
Taxes payable	24,559,352.80	76,076,252.32
Other payables	28,729,176.42	30,704,212.73
Including: Interests payable		
Dividends payable		
Non-current liabilities due within one year	81,888,469.20	45,067,562.07
Other current liabilities	124,860.66	4,863,465.79
Total current liabilities	1,633,066,929.42	2,001,453,257.95
Non-current liabilities:		
Long-term borrowings	776,104,867.88	490,000,000.00
Lease liabilities	136,794,202.80	93,126,619.21
Deferred income	122,237,117.39	122,458,529.87
Other non-current liabilities	8,481,444.79	11,498,407.24
Total non-current liabilities	1,043,617,632.86	717,083,556.32
Total liabilities	2,676,684,562.28	2,718,536,814.27
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	912,601,900.00	910,756,700.00
Capital reserve	11,647,437,221.22	11,422,714,543.28
Other comprehensive income	-20,982,233.18	209,175.29
Retained earnings	-5,983,314,584.38	-4,388,585,020.16
Total owners' equity (or shareholders' equity) attributable to equity holders of the Company	6,555,742,303.66	7,945,095,398.41
Minority interests	348,604,342.86	371,278,888.27
Total owners' equity (or shareholders' equity)	6,904,346,646.52	8,316,374,286.68
Total liabilities and owners' equity (or shareholders' equity)	9,581,031,208.80	11,034,911,100.95

Legal Representative: Xiong Jun   Chief Financial Officer: Xu Baohong

Head of Accounting Department: Cai Jingwu

CONSOLIDATED INCOME STATEMENT

January to September 2022

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan   Currency: RMB   Audit type: Unaudited

Items	First three quarters of 2022 (January to September)	First three quarters of 2021 (January to September)
1. Total operating income	1,218,381,861.73	2,718,396,641.58
Including: Operating income	1,218,381,861.73	2,718,396,641.58
2. Total operating costs	2,932,404,943.14	3,138,462,309.55
Including: Operating costs	427,310,088.48	750,100,610.99
Taxes and surcharges	7,034,614.26	5,059,716.69
Selling and distribution expenses	513,767,133.45	527,443,356.23
Administrative expenses	419,516,196.83	428,191,758.80
Research and development expenses	1,636,118,643.63	1,422,572,326.73
Financial expenses	-71,341,733.51	5,094,540.11
Including: Interest expenses	18,308,694.94	26,921,129.50
Interest income	42,148,367.67	24,991,682.09
Add: Other income	19,765,259.31	35,138,705.83
Investment income (Loss is indicated by “-”)	-18,744,166.06	-31,949,820.39
Including: Income from investments in associates and joint ventures	-47,843,190.08	-32,735,573.81
Income from changes in fair value (Loss is indicated by “-”)	-16,717,008.67	141,340,221.35
Impairment loss of credit (Loss is indicated by “-”)	115,411.19	418,787.06
Impairment loss of assets (Loss is indicated by “-”)	-18,600,893.60	-14,231,351.81
Income from disposal of assets (Loss is indicated by “-”)	32,195,812.68	805,981.39
3. Operating profit (Loss is indicated by “-”)	-1,716,008,666.56	-288,543,144.54
Add: Non-operating income	192,195.45	46,951.73
Less: Non-operating expenses	11,041,260.44	23,790,964.33
4. Total profit (Total loss is indicated by “-”)	-1,726,857,731.55	-312,287,157.14
Less: Income tax expenses	7,681,222.13	79,839,729.45
5. Net profit (Loss is indicated by “-”)	-1,734,538,953.68	-392,126,886.59
(I) Categorized by the nature of continuing operation		
1. Net profit from continuing operations (Net loss is indicated by “-”)	-1,734,538,953.68	-392,126,886.59
2. Net profit from discontinued operations (Net loss is indicated by “-”)		
(II) Categorized by ownership		
1. Net profit attributable to the shareholders of the Company (Net loss is indicated by “-”)	-1,594,729,564.22	-392,126,592.23
2. Profit or loss attributable to minority interests (Net loss is indicated by “-”)	-139,809,389.46	-294.36
6. Other comprehensive income, net of tax	-21,191,408.47	23,685,896.13

(I) Other comprehensive income attributable to the owners of the Company, net of tax	-21,191,408.47	23,685,896.13
1. Other comprehensive income that cannot be subsequently reclassified to profit or loss	-83,549,115.92	25,595,074.18
(1) Changes of the re-measurement in defined benefit plans		
(2) Other comprehensive income that cannot be subsequently reclassified to profit or loss under the equity method		
(3) Changes in fair value of other equity instruments investments	-83,549,115.92	25,595,074.18
(4) Changes in fair value of the enterprise's own credit risk		
2. Other comprehensive income that will be reclassified to profit or loss	62,357,707.45	-1,909,178.05
(1) Other comprehensive income that will be transferred to profit or loss under the equity method		
(2) Changes in fair value of other debt investments		
(3) Amount of financial assets that are reclassified to other comprehensive income		
(4) Impairment provision for credit of other debt investments		
(5) Cash flow hedge reserves		
(6) Translation differences of financial statements denominated in foreign currencies	62,357,707.45	-1,909,178.05
(7) Others		
(II) Other comprehensive income attributable to minority interests, net of tax		
7. Total comprehensive income	-1,755,730,362.15	-368,440,990.46
(I) Total comprehensive income attributable to owners of the parent company	-1,615,920,972.69	-368,440,696.10
(II) Total comprehensive income attributable to minority interests	-139,809,389.46	-294.36
8. Earnings per share:		
(I) Basic earnings per share (yuan/share)	-1.75	-0.44
(II) Diluted earnings per share (yuan/share)	-1.75	-0.44

In respect of the merger of entities under common control that occurred during the current period, net profit of the entity being merged realized before the merger was nil. Net profit of the entity being merged realized during the previous period was nil.

Legal Representative: Xiong Jun Chief Financial Officer: Xu Baohong

Head of Accounting Department: Cai Jingwu

CONSOLIDATED STATEMENT OF CASH FLOWS

January to September 2022

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Items	First three quarters of 2022 (January to September)	First three quarters of 2021 (January to September)
1. Cash flows from operating activities:		
Cash received from the sale of goods and the rendering of services	2,109,423,813.08	2,584,764,961.17
Receipts of tax refunds	291,196,841.84	72,362,699.32
Other cash received in respect of operating activities	28,692,266.66	60,669,882.28
Sub-total of cash inflows from operating activities	2,429,312,921.58	2,717,797,542.77
Cash payments for goods purchased and services received	2,381,182,332.07	2,265,344,173.44
Cash payments to and on behalf of employees	1,004,741,277.72	844,140,353.20
Payments of various types of taxes	22,444,479.82	22,576,748.00
Other cash payments relating to operating activities	138,434,053.16	125,857,661.94
Sub-total of cash outflows from operating activities	3,546,802,142.77	3,257,918,936.58
Net cash flows from operating activities	-1,117,489,221.19	-540,121,393.81
II. Cash flow from investing activities:		
Cash received from recovery of investments	91,000,000.00	303,990,009.53
Cash received from investment income	244,527.26	785,753.42
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	660.00	873.07
Other cash received in respect of investing activities	42,043,518.85	24,991,682.09
Sub-total of cash inflows from investing activities	133,288,706.11	329,768,318.11
Cash payments to acquire or construct fixed assets, intangible assets and other long-term assets	284,140,853.20	660,708,467.91
Cash paid for investments	195,484,047.00	1,105,268,305.29
Other cash payments relating to investing activities		20,000,000.00
Sub-total of cash outflows from investing activities	479,624,900.20	1,785,976,773.20
Net cash flows from investing activities	-346,336,194.09	-1,456,208,455.09
III. Cash flows from financing activities:		
Cash received from investors	396,975,840.00	2,121,734,262.98
Including: Cash received from capital contributions by minority shareholders of subsidiaries	380,000,000.00	

Cash received from borrowings	768,205,172.19	500,000,000.00
Other cash received in respect of financing activities	1,301,133.76	
Sub-total of cash inflows from financing activities	1,166,482,145.95	2,621,734,262.98
Cash repayments of borrowings	10,000,000.00	793,333,333.34
Cash payments for distribution of dividends, or profits or settlement of interest expenses	16,973,851.39	27,614,111.12
Including: Cash payments for distribution of dividends or profits to minority shareholders of subsidiaries		
Other cash payments relating to financing activities	286,105,174.95	30,774,685.44
Sub-total of cash outflows from financing activities	313,079,026.34	851,722,129.90
Net cash flows from financing activities	853,403,119.61	1,770,012,133.08
IV. Effect of foreign exchange rate changes on cash and cash equivalents	107,232,199.06	-11,220,345.39
V. Net increase in cash and cash equivalents	-503,190,096.61	-237,538,061.21
Add: Balance of cash and cash equivalents at the beginning of the period	3,504,604,838.72	3,384,997,561.89
VI. Balance of cash and cash equivalents at the end of the period	3,001,414,742.11	3,147,459,500.68

Legal Representative: Xiong Jun Chief Financial Officer: Xu Baohong

Head of Accounting Department: Cai Jingwu

Adjustments made to relevant items of the financial statements as at the beginning of the year of the initial adoption of new accounting standards or interpretations of standards in 2022

□Applicable √Not applicable

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

28 October 2022

** For identification purpose only*